• JNK-IN-7: Selective JNK Inhibitor for Apoptosis & Signaling

  2026-06-18

  JNK-IN-7 is a selective JNK inhibitor with nanomolar potency that enables precise dissection of MAPK signaling and apoptosis pathways. Its covalent inhibition of JNK isoforms supports advanced research in inflammation and innate immune modulation.

• DMG-PEG2000-NH2: Redefining Lipid-Based Drug Delivery Platfo

  2026-06-17

  This article explores the mechanistic strengths and translational strategies unlocked by DMG-PEG2000-NH2, an advanced NH2-PEG derivative. We synthesize current evidence and competitive insights for researchers optimizing lipid nanoparticle (LNP) and liposomal platforms, emphasizing practical protocol parameters and the evolving therapeutic landscape.

• RNA Pol II Inhibition Triggers Apoptosis via Pol IIA Loss, N

  2026-06-17

  Harper et al. (2025) uncover that inhibiting RNA Pol II activates a regulated apoptotic pathway independent of transcriptional shutdown, triggered specifically by depletion of hypophosphorylated RNA Pol IIA. This mechanistic insight reframes how cell death is initiated during transcriptional inhibition and has implications for cancer therapy development.

• SHC-1 Inhibition Enhances CFTR Surface Abundance in Epitheli

  2026-06-16

  This study reveals how SHC-1, via the MAPK pathway, regulates the internalization and plasma membrane abundance of the CFTR chloride channel in various epithelial cell models. By comparing pharmacological SHC-1 inhibitors, the research clarifies cell-type-specific responses, informing assay design and mechanistic understanding for cystic fibrosis and secretory diarrheal disease research.

• SmD2 Acetylation Regulates Splicing and PARP Sensitivity in

  2026-06-16

  This study uncovers how acetylation-dependent regulation of the spliceosome core component SmD2 influences alternative splicing and DNA damage response in hepatocellular carcinoma (HCC). By linking HDAC2-mediated deacetylation of SmD2 to splicing control and demonstrating that HDAC inhibition (via Romidepsin) synergizes with PARP inhibition, the paper identifies new combinatorial therapeutic strategies for HCC.

• Lypressin Acetate (SKU N2888): Reliable Solutions for Vasopr

  2026-06-15

  This authoritative article addresses real-world laboratory challenges in cell viability, proliferation, and vasopressor assays, demonstrating how Lypressin acetate (SKU N2888) from APExBIO provides reproducible and data-backed solutions. Practical Q&A scenarios, protocol guidance, and comparative insights ensure that biomedical researchers and lab technicians can optimize workflows with confidence.

• Cholesterol Impairs Lipid Nanoparticle Trafficking in Cells

  2026-06-15

  This study reveals that increased cholesterol content in lipid nanoparticles (LNPs) hinders their intracellular trafficking and reduces nucleic acid delivery efficiency. Through a sensitive imaging platform, the authors identify cholesterol-dependent trapping of LNPs in peripheral endosomes, highlighting key formulation variables that impact delivery outcomes.

• Optimizing In Vitro Assays with A23187, Free Acid (SKU B6646

  2026-06-14

  This evidence-based guide explores how A23187, free acid (SKU B6646) enhances reproducibility and mechanistic clarity in cell viability, apoptosis, and calcium signaling assays. By addressing real-world laboratory challenges, the article demonstrates the scientific and practical value of integrating this calcium ionophore into advanced experimental workflows.

• Harnessing Balsalazide Disodium for Translational IBD Innova

  2026-06-13

  This article explores the mechanistic and strategic value of Balsalazide Disodium Dihydrate for translational researchers in inflammatory bowel disease (IBD). Blending mechanistic insight with actionable protocol guidance, it highlights how colonic-targeted prodrug activation, streamlined immunology assay workflows, and emerging roles in imaging and pathway inhibition collectively empower next-generation IBD research. Drawing on peer-reviewed literature and scenario-driven applications, the article situates APExBIO's offering within the broader competitive landscape while providing a forward-looking perspective on translational innovation.

• AP20187: Precision Chemical Inducer of Dimerization Workflow

  2026-06-12

  AP20187 empowers tunable protein interaction and conditional gene therapy activation with robust reproducibility, thanks to its exceptional solubility and validated in vivo efficacy. This guide details optimized protocols, troubleshooting strategies, and translational advances that set AP20187 apart for fusion protein dimerization and pathway regulation.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-06-12

  Clasto-Lactacystin β-lactone empowers researchers with potent, irreversible proteasome inhibition—crucial for dissecting protein degradation, apoptosis, and disease modeling. Its high selectivity and cell-permeability streamline ubiquitin-proteasome pathway research with reproducible, interpretable outcomes.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-06-12

  Clasto-Lactacystin β-lactone empowers researchers with potent, irreversible proteasome inhibition—crucial for dissecting protein degradation, apoptosis, and disease modeling. Its high selectivity and cell-permeability streamline ubiquitin-proteasome pathway research with reproducible, interpretable outcomes.

• ECL Western Blotting Substrate: Technical Use and Workflow G

  2026-06-11

  ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of HRP-conjugated proteins in chemiluminescent Western blot assays. It is suited for protein detection workflows in molecular biology, cancer biology, and signal transduction research, but should not be used for protocols requiring fluorescent or radioisotopic detection.

• Region-Specific Uptake of Milk EVs in Porcine Intestinal Org

  2026-06-11

  This study introduces physiologically relevant porcine intestinal stem cell–based organoid models to clarify how milk-derived extracellular vesicles (MEV) are internalized and influence stemness and differentiation. The findings provide new mechanistic insight into region- and polarity-specific vesicle uptake, advancing endocytosis and membrane trafficking research in the context of intestinal physiology.

• Iptacopan (LNP023): Applied Protocols for Complement Pathway

  2026-06-10

  Iptacopan (LNP023) enables precise, highly selective inhibition of the alternative complement pathway, revolutionizing both in vitro and in vivo research on complement-mediated diseases. This guide details optimized workflows, troubleshooting strategies, and actionable protocol enhancements based on recent translational advances.

11408 records 7/761 page Previous Next First page 上5页 678910 下5页 Last page